Codonopsis lanceolata ameliorates sarcopenic obesity via recovering PI3K/Akt pathway and lipid metabolism in skeletal muscle

Han, Min Ji; Choung, Se‐Young

doi:10.1016/j.phymed.2021.153877

Cited by 13 publications

(10 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As energy metabolism is closely related to protein metabolism in the skeletal muscle [ 59 ], reduced muscle weight or lean mass contributes to energy metabolism dysregulation in skeletal muscle [ 60 ]. In skeletal muscle, phosphatidylinositol-3-kinase (PI3K)/protein kinase B (Akt) is a muscle metabolism regulator that induces muscle protein synthesis through the phosphorylation of protein S6 kinase 1 (S6K1) and eukaryotic translation initiation factor 4E (elF4E)-binding protein 1 (4E-BP1) [ 61 ]. On the other hand, phosphorylated Akt inhibits protein degradation through inhibition of Muscle RING finger 1 (MuRF1) and muscle atrophy F-box (MAFbx/Atrogin-1), which are muscle-specific E3 ubiquitin ligases mediated by forkhead box O3a (FoxO3a) [ 62 ].…”

Section: Discussionmentioning

confidence: 99%

Effects of Whey Peptide Supplementation on Sarcopenic Obesity in High-Fat Diet-Fed Mice

Lim

2022

Nutrients

View full text Add to dashboard Cite

The incidence of sarcopenic obesity gradually increased in parallel with the aged population. This research examined the effects of whey peptide (WP) supplementation with/without resistant exercise (RE) on sarcopenic obesity. Male 8-month-old C57BL/6J mice were fed a control diet (10 kcal% fat) or a high-fat diet (60 kcal% fat) for 8 weeks. High-fat diet-fed mice were randomly divided into four groups: obesity control group (OB), RE (RE only), WP (WP only), and WPE (RE and WP). WP supplementation (1500 mg/day/kg B.W.) gavage and RE (ladder climbing, five times weekly, 8–10 repetitions, 10–20% B.W. load) were conducted for an additional 8 weeks. Protein and mRNA levels of markers related to energy, protein, and lipid metabolism were analyzed in skeletal muscle and adipose tissue by one-way analysis of variance (ANOVA). WP supplementation regardless of RE significantly suppressed the increasing fat mass (p = 0.016) and decreasing lean mass (p = 0.014) and alleviated abnormal morphological changes in skeletal muscle and adipose tissue (p < 0.001). In adipose tissue, WP supplementation regardless of RE ameliorated dysregulated energy metabolism and contributed to the reduction in adipocyte differentiation (PPAR-γ (p = 0.017), C/EBPα (p = 0.034)). In skeletal muscle, WP supplementation regardless of RE alleviated energy metabolism dysregulation and resulted in down-regulated protein degradation (Atrogin-1 (p = 0.003), MuRF1 (p = 0.006)) and apoptosis (Bax) (p = 0.004). Taken together, the current study elucidated that WP supplementation regardless of RE has potential anti-obesity and anti-sarcopenic effects in sarcopenic obesity.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of Whey Peptide Supplementation on Sarcopenic Obesity in High-Fat Diet-Fed Mice

Lim

2022

Nutrients

View full text Add to dashboard Cite

show abstract

“…[16] C lanceolata has shown positive changes in muscle. [20,21] Therefore, this high-quality randomized controlled trial protocol was designed for a large-scale, double-blind clinical trial using C lanceolata water extract. This study is the first clinical trial of C lanceolata water extract in adults with reduced muscle strength.…”

Section: Discussionmentioning

confidence: 99%

“…It may reduce muscle protein degradation by inhibiting the expression of muscle atrophy F-box protein (Atrogin-1) and muscle ring finger-1 (MuRF1), [ 20 ] and is also effective in sarcopenic obesity by inhibiting the accumulation of lipids in the skeletal muscle by restoring the activating protein kinase B and phosphatidylinositol-3-kinase pathways and lipid metabolism. [ 21 ] However, few clinical trials have directly used C lanceolata water extract for the treatment of sarcopenia.…”

Section: Introductionmentioning

confidence: 99%

The efficacy and safety of Codonopsis lanceolata water extract for sarcopenia: A study protocol for randomized, double-blind, placebo-controlled clinical trial

et al. 2022

Self Cite

View full text Add to dashboard Cite

Introduction: This study aimed to propose a protocol to demonstrate the efficacy of Codonopsis lanceolata water extract for the improvement of skeletal muscle mass (SMM) and function (muscle strength or performance function) and its safety compared to a placebo in adults with reduced muscle strength. Methods and analysis: A randomized double-blind placebo-controlled clinical trial was conducted. Participants will be recruited from the Korean Medicine Hospital in South Korea. One hundred and four adults with reduced muscle strength will be randomly assigned a 1:1 ratio to either the experimental or placebo comparator groups. The participants will consume the product corresponding to their assigned group for the following 12 weeks, and efficacy and safety tests will be conducted. This is the first clinical trial of C lanceolata water extract in adults with reduced muscle strength. The results of this study would provide a clinical basis for the efficacy and safety of C lanceolata water extract in patients with sarcopenia. Ethics and dissemination: This trial was approved by the Institutional Review Board (IRB) of Kyung Hee University Korean Medicine Hospital at Gangdong on July 15, 2021 (amendment number: MLB_DDE_H01 [ver. 01]). When a change was made in the clinical trial plan, the IRB reviewed and approved the revised clinical trial plan. The study was registered on the Clinical Research Information Service website on December 3, 2021 (registration number: PRE20211203-003; https://cris.nih.go.kr/cris/search/detailSearch.do?seq=20841&status=1&seq_group=20841&search_page=M ). The results of this clinical trial will be reported in the future. Every document related to the clinical trial, such as the electronic case report form, will be recorded and classified by the subject identification code and not by the subject name.

show abstract

“…20,[23][24][25] Several studies have confirmed that an HFD decreases the phosphorylation level of Akt/ mTOR/p70S6K and increases the expression of MAFbx and MuRF1 in the liver or skeletal muscle. [26][27][28] However, the mechanism by which obesity affects these signaling pathways requires further investigation.…”

Section: Introductionmentioning

confidence: 99%

“…MAFbx and MuRF1 are factors in the skeletal muscle‐specific ubiquitin‐proteasome system, which is a major degradation system for myoprotein mass control in skeletal muscle 20,23–25 . Several studies have confirmed that an HFD decreases the phosphorylation level of Akt/mTOR/p70S6K and increases the expression of MAFbx and MuRF1 in the liver or skeletal muscle 26–28 . However, the mechanism by which obesity affects these signaling pathways requires further investigation.…”

Section: Introductionmentioning

confidence: 99%

Nur77 is involved in the regulation of obesity‐related lower muscle mass by promoting Pten degradation

Chen

Tian

et al. 2023

The FASEB Journal

View full text Add to dashboard Cite

Obesity may impair muscle function and is sometimes associated with lower muscle mass. However, the internal regulatory mechanism is still unclear. Nur77 has been reported to improve obesity phenotype by regulating glucose and lipid metabolism and inhibiting the production of inflammatory factors and reactive oxygen species. Concurrently, Nur77 also plays an important role in muscle differentiation and development. We aimed to investigate the role of Nur77 in obesity‐related lower muscle mass. Our in vivo and in vitro experiments illustrated that the reduction of obesity‐related Nur77 accelerated the occurrence of lower muscle mass by interfering with the signaling pathways involved in the regulation of myoprotein synthesis and degradation. We further demonstrated that Nur77 activates the PI3K/Akt pathway by promoting Pten degradation, which enhances the phosphorylation of the Akt/mTOR/p70S6K pathway and inhibits the expression of skeletal muscle‐specific E3 ligases (MAFbx/MuRF1). Nur77 induces Pten degradation by increasing the transcription of its specific E3 ligase Syvn1. Our study confirms that Nur77 is a key factor in ameliorating obesity‐related lower muscle mass, providing a new therapeutic target and theoretical basis for the treatment of obesity‐related lower muscle mass.

show abstract

Codonopsis lanceolata ameliorates sarcopenic obesity via recovering PI3K/Akt pathway and lipid metabolism in skeletal muscle

Cited by 13 publications

References 29 publications

Effects of Whey Peptide Supplementation on Sarcopenic Obesity in High-Fat Diet-Fed Mice

Effects of Whey Peptide Supplementation on Sarcopenic Obesity in High-Fat Diet-Fed Mice

The efficacy and safety of Codonopsis lanceolata water extract for sarcopenia: A study protocol for randomized, double-blind, placebo-controlled clinical trial

Nur77 is involved in the regulation of obesity‐related lower muscle mass by promoting Pten degradation

Contact Info

Product

Resources

About